Singapore, May 16 -- Rznomics Inc., aSouth Korea-based biopharmaceutical startup specialising in RNA-based therapeutics, has entered into a strategic global research collaboration and licensing agreement with Eli Lilly and Companyto develop and commercialise novel RNA-editing therapies using Rznomics' proprietary trans-splicing ribozyme platform.

The collaboration focuses on the discovery and development of RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialization.

If Lilly exercises all available options under the agreement, the total deal value could reach more...